Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C-Reference-Cited by-同舟云学术

Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C

Published:2020-05-04 Issue:10 Volume:94 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Tartaglia Lawrence J.¹,Gupte Siddhant¹,Pastores Kevin C.¹,Trott Sebastien¹,Abbink Peter¹,Mercado Noe B.¹,Li Zhenfeng¹,Liu Po-Ting¹,Borducchi Erica N.¹,Chandrashekar Abishek¹,Bondzie Esther Apraku¹,Hamza Venous¹,Kordana Nicole¹,Mahrokhian Shant¹,Lavine Christy L.¹,Seaman Michael S.¹,Li Hui²,Shaw George M.²,Barouch Dan H.¹³

Affiliation:

1. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

2. Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

3. Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA

Abstract

We sought to enhance the infectivity of three SHIV stocks by optimization of a key residue in human immunodeficiency virus type 1 (HIV-1) Env (Env375). We developed the following three new simian-human immunodeficiency virus (SHIV) stocks: SHIV-SF162p3S/wild type, SHIV-AE16W, and SHIV-325cH. SHIV-SF162p3S could not be optimized, SHIV-AE16W proved comparable to the parental virus, and SHIV-325cH demonstrated markedly enhanced replicative capacity compared with the parental virus.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Ragon Institute of MGH, MIT and Harvard

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.01860-19

Reference26 articles.

1. Utility of SHIV for Testing HIV-1 Vaccine Candidates in Macaques

2. Development of SHIVs with circulating, transmitted HIV-1 variants